C12N5/07

Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells
09757422 · 2017-09-12 ·

Compositions and methods are provided herein for regenerating and repairing damaged or aged tissue or organs using nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods described herein provide anti-aging benefits to the skin by increasing the hydration reducing fine lines, wrinkles, and pores of the skin. Compositions and methods are also provided for promoting wound healing using lyophilized pluripotent stem cell powder. A method is provided for inducing cardiac muscle regeneration in a primate comprising delivering nonviable lethally irradiated pluripotent stem cells to damaged or aged areas of the heart. The compositions and methods include nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods utilize nonviable pluripotent stem cells in the form of a powder, such as lyophilized stem cells.

NUCLEOTIDE-SPECIFIC RECOGNITION SEQUENCES FOR DESIGNER TAL EFFECTORS

The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.

Cell culture medium
RE048864 · 2021-12-28 · ·

The present application describes an optimized medium for growth of mammalian cells as well as polypeptide production. The cell culture medium is characterized by a Sow ratio of sodium to potassium ions, it further relates to the method of producing polypeptides using such cell culture media. Sn another aspect, the method of polypeptide production can also comprise a temperature shift and/or a pH-shift to further optimize growth and product yield.

Mutant fragments of OspA and methods and uses relating thereto

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.

DISSEMINATED NEOPLASIA CELLS AND METHODS OF THEIR USE TO CONTROL INVASIVE OR PEST SPECIES
20210392901 · 2021-12-23 · ·

The current disclosure provides methods and compositions useful in preparing transformed and immortalized zebra and quagga mussel cells that function as disseminated neoplastic (DN) cells, as well as the cells produced thereby. Also provided are methods for using such mussel DNCs in cell culture, in vitro, and within live mussels in the lab or in the wild, to control mussel populations such as invasive zebra mussel or quagga mussel populations.

Microorganism-Derived Protein Hydrolysates and Methods of Preparation and Use Thereof
20210395677 · 2021-12-23 ·

A protein hydrolysate composition derived from a microorganism, such as a chemoautotrophic microorganism, and methods of preparing and using the same are provided. The protein hydrolysate composition may be produced sustainably through fixation of carbon dioxide from biogenic or atmospheric sources. The protein hydrolysate composition finds use in supplementing culture media for serum-free culturing of animal cells as well as for growing other types of cells such as probiotics and lactic acid bacteria. Thus, the present disclosure provides sustainable, humane processes for culturing cells for pharmaceutical and nutraceutical application as well as for human consumption as a food ingredient or product, including cultured meat.

Methods for convectively-driven intracellular delivery

Embodiments of the present disclosure can include a method for convective intracellular delivery including providing cells and molecules to a microchannel having compressive surfaces, wherein the compressive surfaces define compression gaps having a height of from 20 and 80% of the average cell diameter; and a plurality of relaxation spaces disposed between the compressive surfaces; flowing the cell medium through the microchannel, wherein as the cell medium flows through the microchannel, the plurality of cells undergo a convective intracellular delivery process comprising: compressing the plurality of cells, wherein the compressing causes the plurality of cells to undergo a loss in intracellular volume (V.sub.loss); and passing the plurality of cells to a first relaxation space, wherein the plurality of cells undergo a gain in volume (V.sub.gain) and absorb a portion of the plurality of molecules.

ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANS
20210388315 · 2021-12-16 ·

The present disclosure is directed to methods for the formation and production of renewable muscle and/or fat primary cell lines, immortalized cell lines, and stem cell lines from shrimp, prawn, crab, crayfish, and/or lobster species and the cell lines themselves as well as human and animal consumable meat products produced therefrom.

CSFV SUBUNIT VACCINE
20220193221 · 2022-06-23 ·

Provided a recombinant classical swine fever virus E2 protein comprising at least one mutation at the epitope specifically recognized by the 6B8 monoclonal antibody. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.